Site is Being Upgraded

Molecular therapy for body weight control, energy homeostasis and TIIDM: Syringic acid decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 25/February/2017, 9.58 pm

Natural product-based combinatorial therapy for Lifespan extension: A therapeutic mix encompassing  L-Arginine, Catalpol, Cholecalciferol, Maresin, Ursolic acid, DIM, Isoliquiritigenin, & Lutein   (LACCMUDIL) activates autophagy, promotes leanness, increases insulin sensitivity, improves motor function, alleviates ageing feature and extends lifespan via up regulation of its target gene ATG5 (Autophagy related 5), 24/February/2017, 6.42 am
February 24, 2018
Activation of the PD-1 pathway for Pain therapy: Venlafaxine (brand name: effexor), an antidepressant which functions as a selective serotonin-norepinephrine reuptake inhibitor, increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 25/February/2017, 10.16 pm
February 25, 2018
Show all

Introduction: What they say

A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.” This research paper was published, in the June 2017 issue of the journal “Nature Neuroscience” [One of the best research journals in Neuroscience with an I.F of 17.398], by Prof. Matthew N Poy and Thomas Rathjen and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for body weight control, energy homeostasis and TIIDM: Syringic acid decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than half a billion adults are obese worldwide ; (2) obesity is more prevalent in western countries than in asian countries; (3) obesity results in deregulated blood pressure, cholesterol, triglycerides and insulin sensitivity; and the risks of coronary heart disease, ischemic stroke and TII diabetes mellitus(TIIDM) increase ; (4) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (5) Diabetes is going to be one of the top 10 causes of death by 2030; (6) the life-long painful injection/drug treatment is required to treat DM; and  (7) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, obesity-associated diseases, including diabetes.


What is known?

Prof. Matthew N Poy’s research team has recently shown that:(1) Cell adhesion molecule 1 (CADM1) and cell adhesion molecule 2 (CADM2) are over expressed in Obese mice;(2) induction of CADM1 in excitatory neurons promotes weight gain and reduces energy expenditure; and (3) loss of CADM1 protects mice from diet-induced and genetically induced Obesity. Furthermore, decreasing CADM1 levels in mice results in weight loss; and increased energy expenditure, suggesting that decreasing the expression of CADM1 may promote weight loss, augment insulin sensitivity, and alleviate Obesity-associated TIIDM


From research findings to Therapeutic opportunity:

This study suggests a small molecule-based therapy for Weight loss and Obesity-associated TIIDM.    Syringic acid, by increasing the expression of its target gene, it may decrease the expression of CADM1. Thereby, it may: (1) increase pancreatic beta-cell proliferation; (2) increase expression of genes that promote insulin sensitivity and insulin secretion; (3) promote weight loss; (4) augment energy expenditure; (5) decrease metabolic stress; and (6) promote energy homeostasis (Fig.1).

Figure 1. Mechanistic insights into  Syringic acid  promotes weight loss, augments insulin sensitivity and alleviates Obesity-associated TIIDM.

Figure 2. The chemical structures of  Syringic acid.

Thus, pharmacological formulations [PMSF] encompassing Syringic acid  or its analogues, either alone or in combination with other drugs” may be used as a weight-loss medication; and to treat Obesity-associated TIIDM.


 

 

 

 

 

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does  Syringic acid  decrease the expression of CADM1 to promote Weight loss?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Molecular therapy for body weight control, energy homeostasis and TIIDM: Syringic acid decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 25/February/2017, 9.58 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.